Under NIAID's Division of Intramural Research animal care program, Charles River will manage and provide staffing for NIAID's on-site vivarium and related research model operations.
The programme is required to ensure the humane care and use of research models, and the efficient management of NIAID's research model operations.
This contract was awarded on April 20, 2018, and commenced on September 14, 2018. The initial period of the contract runs through September 13, 2019, and it includes annual renewal options to extend the contract for an additional four years through September 13, 2023.
Charles River expects this new contract to generate incremental revenue of approximately USD 18m over the initial twelve-month period, with modest increases in each of the subsequent periods.
The contract is not expected to have a meaningful impact on the company's 2018 financial results because its start date was near the end of 3Q18.
Charles River's Insourcing Solutions business will manage approximately 200 on-site, Charles River personnel to support the NIAID contract, ranging from program management, training, quality control, animal husbandry, veterinary, technical, research, and administrative support staff.
The staff will provide a range of technical and support services required for biomedical research involving multiple scientific disciplines.
The scope of the contracted services includes veterinary medical care, research model husbandry, technical support, data management, routine maintenance, sanitation, transportation, logistics, and administrative support. The services will be provided on location at various NIAID and other government facilities.
Charles River's Insourcing Solutions business offers recruiting, training, staffing and vivarium management services to academic, government and biopharmaceutical clients.
This project will be 100% funded with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services under contract no.
Charles River provides products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial